Meike Brinker

956 total citations · 1 hit paper
39 papers, 333 citations indexed

About

Meike Brinker is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Meike Brinker has authored 39 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Endocrinology, Diabetes and Metabolism, 20 papers in Cardiology and Cardiovascular Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Meike Brinker's work include Hormonal Regulation and Hypertension (23 papers), Diabetes Treatment and Management (15 papers) and Blood Pressure and Hypertension Studies (11 papers). Meike Brinker is often cited by papers focused on Hormonal Regulation and Hypertension (23 papers), Diabetes Treatment and Management (15 papers) and Blood Pressure and Hypertension Studies (11 papers). Meike Brinker collaborates with scholars based in Germany, United States and Denmark. Meike Brinker's co-authors include Peter Rossing, Bertram Pitt, Stefan D. Anker, George L. Bakris, Amer Joseph, Luís M. Ruilope, Gerasimos Filippatos, Hiddo J.L. Heerspink, Rajiv Agarwal and Pantelis Sarafidis and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Meike Brinker

29 papers receiving 325 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

2025 44 citations Rajiv Agarwal, Hiddo J.L. Heerspink et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meike Brinker Germany	12	213	125	87	69	50	39	333
Marc Lambelet Germany	11	120 0.6×	212 1.7×	68 0.8×	40 0.6×	19 0.4×	22	311
Mikhail Kosiborod United States	6	229 1.1×	183 1.5×	48 0.6×	76 1.1×	11 0.2×	13	334
Susanne Jung Germany	11	183 0.9×	175 1.4×	59 0.7×	68 1.0×	48 1.0×	30	364
Yshai Yavin United States	10	262 1.2×	69 0.6×	69 0.8×	98 1.4×	71 1.4×	20	351
Nisha Suda United States	2	201 0.9×	119 1.0×	90 1.0×	72 1.0×	29 0.6×	5	275
Laura Buzzi Italy	11	156 0.7×	154 1.2×	51 0.6×	96 1.4×	123 2.5×	18	390
Charlie Scott United States	10	361 1.7×	129 1.0×	133 1.5×	125 1.8×	50 1.0×	23	462
Marina V. Karg Germany	7	309 1.5×	145 1.2×	68 0.8×	111 1.6×	46 0.9×	17	422
Francesca Palano Italy	13	116 0.5×	475 3.8×	38 0.4×	59 0.9×	26 0.5×	28	590
Hans-Ulrich Haering Germany	8	94 0.4×	84 0.7×	29 0.3×	56 0.8×	21 0.4×	19	247

Countries citing papers authored by Meike Brinker

Since Specialization

Citations

This map shows the geographic impact of Meike Brinker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meike Brinker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meike Brinker more than expected).

Fields of papers citing papers by Meike Brinker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meike Brinker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meike Brinker. The network helps show where Meike Brinker may publish in the future.

Co-authorship network of co-authors of Meike Brinker

This figure shows the co-authorship network connecting the top 25 collaborators of Meike Brinker. A scholar is included among the top collaborators of Meike Brinker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meike Brinker. Meike Brinker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heerspink, Hiddo J.L., Rajiv Agarwal, Antonio J. Amor, et al.. (2025). Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations. Nephrology Dialysis Transplantation. 41(3). 556–565. 1 indexed citations

Navaneethan, Sankar D., Stefan D. Anker, Gerasimos Filippatos, et al.. (2025). Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis. Kidney International. 108(1). 136–144. 7 indexed citations

Singh, Ajay, Stefan D. Anker, Peter Rossing, et al.. (2025). A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD. Kidney International Reports. 11(3). 103704–103704.

Ostrominski, John W., Finnian R. Mc Causland, Brian Claggett, et al.. (2025). Finerenone Across the Spectrum of Kidney Risk in Heart Failure. JACC Heart Failure. 14(1). 102439–102439. 3 indexed citations

Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(7). 1326–1341.

Wanner, Christoph, et al.. (2025). Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data. BMC Nephrology. 26(1). 8–8.

Jongs, Niels, Samvel B. Gasparyan, Lars Frison, et al.. (2025). Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point. Journal of the American Society of Nephrology. 36(12). 2421–2430.

Ostrominski, John W., Brian Claggett, Akshay S. Desai, et al.. (2025). EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology. 85(12). 1167–1167.

Filippatos, Gerasimos, Stefan D. Anker, George L. Bakris, et al.. (2024). Finerenone and Left Ventricular Hypertrophy in Chronic Kidney Disease and Type 2 Diabetes. ESC Heart Failure. 12(1). 185–188. 2 indexed citations

10.

Vaduganathan, Muthiah, Brian Claggett, Ian J. Kulac, et al.. (2024). Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 151(2). 149–158. 25 indexed citations

11.

Bansal, Shweta, Maria Eugênia Fernandes Canziani, Rita Birne, et al.. (2024). Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 14(3). e076444–e076444. 10 indexed citations

12.

Little, Dustin J., Samvel B. Gasparyan, Patrick Schloemer, et al.. (2023). Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review. Journal of the American Society of Nephrology. 34(12). 1928–1935. 11 indexed citations

13.

Eißing, Thomas, Sebastiaan C. Goulooze, Paul van den Berg, et al.. (2023). Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD. Diabetes Obesity and Metabolism. 26(3). 924–936. 8 indexed citations

14.

Filippatos, Gerasimos, Stefan D. Anker, Phyllis August, et al.. (2023). Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 9(2). 183–191. 24 indexed citations

15.

Heerspink, Hiddo J.L., Niels Jongs, Patrick Schloemer, et al.. (2023). Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. Journal of the American Society of Nephrology. 34(12). 2025–2038. 15 indexed citations

16.

Goulooze, Sebastiaan C., et al.. (2022). Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. Clinical Pharmacokinetics. 61(7). 1013–1025. 12 indexed citations

17.

Rossing, Peter, Justus G. Garweg, Stefan D. Anker, et al.. (2022). Effect of finerenone on the occurrence of vision‐threatening complications in patients with non‐proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants ( ReFineDR / DeFineDR ). Diabetes Obesity and Metabolism. 25(3). 894–898. 14 indexed citations

18.

Wanner, Christoph, Johannes Schuchhardt, Chris Bauer, et al.. (2022). Clinical characteristics and disease outcomes in non-diabetic chronic kidney disease: retrospective analysis of a US healthcare claims database. Journal of Nephrology. 36(1). 45–54. 7 indexed citations

19.

Agarwal, Rajiv, Stefan D. Anker, Bertram Pitt, et al.. (2021). Association of Urine Albumin-to-Creatinine Ratio and Its Early Change with Cardiorenal Outcomes in FIDELIO-DKD: A Mediation Analysis. Journal of the American Society of Nephrology. 32(10S). B5–B5.

20.

Goulooze, Sebastiaan C., Meike Brinker, Amer Joseph, et al.. (2021). Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clinical Pharmacokinetics. 61(3). 451–462. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact